Pharming Group EBITDA 2013-2024 | PHGUF

Pharming Group ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Pharming Group EBITDA 2013-2024 | PHGUF

Pharming Group ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$141.6B
Bristol Myers Squibb (BMY)$116.3B
Gilead Sciences (GILD)$115.4B
Vertex Pharmaceuticals (VRTX)$102.3B
CSL (CSLLY)$83.8B
Regeneron Pharmaceuticals (REGN)$77.1B
GSK (GSK)$69.6B
Argenex SE (ARGX)$37.7B
Alnylam Pharmaceuticals (ALNY)$31.7B
BioNTech SE (BNTX)$27.1B
Illumina (ILMN)$21.6B
Biogen (BIIB)$21.3B
BeiGene (BGNE)$17.2B
Moderna (MRNA)$15.2B
Genmab (GMAB)$13.4B
Incyte (INCY)$13.3B
Insmed (INSM)$12.6B
BioMarin Pharmaceutical (BMRN)$12.5B
Bio-Techne Corp (TECH)$11.6B
Sarepta Therapeutics (SRPT)$11.4B
Exact Sciences (EXAS)$11B
Vaxcyte (PCVX)$10.8B
QIAGEN (QGEN)$10.2B
Swedish Orphan Biovitrum (BIOVF)$10.2B
Exelixis (EXEL)$9.5B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.8B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.3B
Repligen (RGEN)$8.1B